H.R. 4299 · 119th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

Introduced on Jul 7, 2025 by Gregory F. Murphy (R-NC-3). 52 cosponsors, 16 of them from another party. Latest action (Jul 7, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Stage
Introduced
Introduced
Jul 7, 2025
Cosponsors
52
16 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend title XVIII of the Social Security Act to provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation.

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Gregory F. MurphyR-NC-3Sponsor

Democrats · 16

Republicans · 36

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Jul 7, 2025Introduced in House
  2. Jul 7, 2025Introduced in House
  3. Jul 7, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Jul 7, 2025 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. Infusion Providers Alliance10 reports
    $540K reported (all issues)
  2. BRISTOL-MYERS SQUIBB COMPANY8 reports
    $8.9M reported (all issues)Federal contractor: BRISTOL-MYERS SQUIBB COMPANY$8.8M in contracts, FY2026AI match · 100%
  3. TAKEDA PHARMACEUTICALS AMERICA, INC.7 reports
    Federal contractor: TAKEDA PHARMACEUTICALS AMERICA, INC.$1.6M in contracts, FY2026AI match · 100%
  4. GENENTECH INC.6 reports
    Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  5. MERCK & CO., INC.6 reports
    Federal contractor: MERCK SHARP & DOHME LLC$445.3K in contracts, FY2026AI match · 100%
  6. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA6 reports
    $9M reported (all issues)
  7. Daiichi Sankyo, Inc.5 reports
    Federal contractor: DAIICHI SANKYO, INC$205.9K in contracts, FY2026AI match · 100%
  8. Large Urology Group Practice Association5 reports
    $450K reported (all issues)
  9. Large Urology Group Practice Association (LUGPA)5 reports
    $300K reported (all issues)
  10. AMERICAN COLLEGE OF RHEUMATOLOGY4 reports
    $300K reported (all issues)
  11. ASSOCIATION FOR CLINICAL ONCOLOGY4 reports
    $920K reported (all issues)
  12. CARDINAL HEALTH INC.4 reports
    $2.9M reported (all issues)Federal contractor: CARDINAL HEALTH 200, LLC$276.6M in contracts, FY2026AI match · 100%
  13. Community Oncology Alliance4 reports
    $1M reported (all issues)
  14. Genentech USA, Inc.4 reports
    $200K reported (all issues)Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  15. JOHNSON & JOHNSON SERVICES, INC.4 reports
    $8.9M reported (all issues)
  16. McKesson Corporation & affiliates U.S. Oncology and Rx Savings Solutions4 reports
    $3.1M reported (all issues)
  17. McKesson Corporation & affiliates U.S. Oncology and Rx Savings Solutions (Former4 reports
    $120K reported (all issues)
  18. ABBVIE3 reports
    $4.6M reported (all issues)Federal contractor: ABBVIE US LLC$154.6K in contracts, FY2026AI match · 100%
  19. AMGEN INC.3 reports
    $5M reported (all issues)Federal contractor: AMGEN INC.AI match · 99%
  20. ASSOCIATION OF CANCER CARE CENTERS (FKA ASSOCIATION OF COMMUNITY CANCER CENTERS)3 reports
    $30K reported (all issues)
  21. CENCORA, INC.3 reports
    $3.6M reported (all issues)
  22. Ferring Pharmaceuticals Inc.3 reports
    $760K reported (all issues)Federal contractor: FERRING PHARMACEUTICALS INC$45.8K in contracts, FY2026AI match · 100%
  23. GILEAD SCIENCES, INC.2 reports
    Federal contractor: GILEAD SCIENCES INCAI match · 100%
  24. GSK (fka GLAXOSMITHKLINE INC.)2 reports
    $2.5M reported (all issues)
  25. McKesson Corpation and its Affiliate US Oncology (formerly US Oncology)2 reports
    $120K reported (all issues)
  26. PACT Coalition2 reports
    $100K reported (all issues)
  27. Alliance for Aging Research1 report
    $70K reported (all issues)
  28. NYU Langone Hospitals (Formerly NYU Hospitals Center)1 report
    $50K reported (all issues)
  29. PFIZER INC.1 report
    $1.9M reported (all issues)Federal contractor: PFIZER INCAI match · 100%
  30. PhRMA Inc.1 report
    $50K reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 7, 2026 · loaded Oct 7, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 7, 2026 · loaded Oct 7, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.